Analyze Diet
Applied microbiology1971; 21(5); 860-861; doi: 10.1128/am.21.5.860-861.1971

Heat-labile factor necessary for hemagglutination-inhibition testing of horse sera.

Abstract: Normal and immune sera were obtained from horses immunized with either aqueous, alum, or adjuvant bivalent vaccines containing Milford equine 2 virus. Upon heating at 56 C for 30 min, a factor, required for hemagglutination-inhibition but not complement fixation or neutralization testing, was destroyed. This factor which is present in normal sera does not appear to be complement.
Publication Date: 1971-05-01 PubMed ID: 5574319PubMed Central: PMC377297DOI: 10.1128/am.21.5.860-861.1971Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines a heat-labile factor involved in hemagglutination-inhibition tests carried out on horse sera. This factor, originally found in normal sera and not complement, gets destroyed on being heated at approximately 56 degrees Celsius for half an hour.

Research Context

  • The study primarily centers around hemagglutination-inhibition testing conducted on horse sera, specifically those immunized with Milford equine 2 virus.
  • The types of sera examined in the research were both normal and immune ones.
  • The process of immunizing the horses for the purpose of the experiment involved the use of aqueous, alum, or adjuvant bivalent vaccines.

Observations and Findings

  • The primary discovery of the research revolves around a specific factor, which coexists with normal sera. This particular factor plays a crucial role in hemagglutination-inhibition testing and hence its identification is of high importance.
  • Interestingly, this vital factor was found not to be present in complement fixation or neutralization testing, which increases its uniqueness and exclusive association with hemagglutination-inhibition testing.
  • Upon heating at a temperature of 56 degrees Celsius for a duration of 30 minutes, the factor was destroyed. This signifies it being a heat-labile factor, susceptible to high temperature, thereby shedding light on its thermal sensitivity.

Implications

  • This kind of research opens up new gateways in the understanding of horse sera and its multiple components, optics one important property of this factor that is its sensitivity to heat.
  • Being fundamental to hemagglutination-inhibition testing, the understanding of this factor and its properties can potentially influence the success rate of these tests in general.

Cite This Article

APA
DeMeio JL, DeSanctis AN. (1971). Heat-labile factor necessary for hemagglutination-inhibition testing of horse sera. Appl Microbiol, 21(5), 860-861. https://doi.org/10.1128/am.21.5.860-861.1971

Publication

ISSN: 0003-6919
NlmUniqueID: 7605802
Country: United States
Language: English
Volume: 21
Issue: 5
Pages: 860-861

Researcher Affiliations

DeMeio, J L
    DeSanctis, A N

      MeSH Terms

      • Adjuvants, Immunologic
      • Animals
      • Antibodies / analysis
      • Complement Fixation Tests
      • Hemagglutination Inhibition Tests
      • Hemagglutination Tests
      • Horses / immunology
      • Hot Temperature
      • Immune Sera
      • Influenza Vaccines
      • Neutralization Tests
      • Vaccination

      References

      This article includes 4 references
      1. McQueen JL, Davenport FM, Minuse E. Studies of equine influenza in Michigan, 1963. I. Etiology.. Am J Epidemiol 1966 Mar;83(2):271-9.
      2. DeMeio JL, Gutekunst DE, Beiler JM, Paton IM, DeSanctis AN. The evaluation of an experimental bivalent equine influenza virus vaccine.. J Am Vet Med Assoc 1969 Jul 15;155(2):278-81.
        pubmed: 4307795
      3. GELLER P, COLEMAN VR, JAWETZ E. Studies on herpes simplex virus. V. The fate of viable herpes simplex virus administered intravenously to man.. J Immunol 1953 Dec;71(6):410-8.
        pubmed: 13118180
      4. CHANOCK RM. Association of a new type of cytopathogenic myxovirus with infantile croup.. J Exp Med 1956 Oct 1;104(4):555-76.
        pubmed: 13367330doi: 10.1084/jem.104.4.555google scholar: lookup

      Citations

      This article has been cited 3 times.
      1. Jia J, Zhang H, Liang X, Dai Y, Liu L, Tan K, Ma R, Luo J, Ding Y, Ke C. Application of Metabolomics to the Discovery of Biomarkers for Ischemic Stroke in the Murine Model: a Comparison with the Clinical Results. Mol Neurobiol 2021 Dec;58(12):6415-6426.
        doi: 10.1007/s12035-021-02535-2pubmed: 34532786google scholar: lookup
      2. O'Brien TC, Hannah JE, Tauraso NM. Heat-labile accessory factor involved in vaccinia virus plaque neutralization. Arch Gesamte Virusforsch 1973;40(3):366-74.
        doi: 10.1007/BF01242557pubmed: 4735532google scholar: lookup
      3. Hierholzer JC, Gamble WC, Quist KD, Chappell WA. Comparison of immunization methods for producing reference adenovirus antisera in horses. Appl Microbiol 1972 Sep;24(3):398-404.
        doi: 10.1128/am.24.3.398-404.1972pubmed: 4562476google scholar: lookup